Novartis: Malaria trials
The registry lists 24 Malaria studies with Novartis as lead sponsor. 3 are open to participants now and 10 have results posted.
Phase 1 6Phase 2 8Phase 3 5Phase 4 5No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and RwandaNot yet recruitingNCT07896746
- Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated MalariaNot yet recruitingNCT07713602Phase 4
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum MalariaRecruitingNCT05750628Phase 2
- Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum MalariaCompletedNCT05842954Phase 3Results posted
- To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum MalariaCompletedNCT04675931Phase 2Results posted
- Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy SubjectsCompletedNCT04321252Phase 1Results posted
- Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum MalariaTerminatedNCT04300309Phase 2/3Results posted
- Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.CompletedNCT03334747Phase 2Results posted
- A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum MonoinfectionCompletedNCT01836458Phase 2Results posted
- Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infectionCompletedNCT01753323Phase 2Results posted
- Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kgCompletedNCT01619878Phase 2/3Results posted
- A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)CompletedNCT01256658Phase 4Results posted
- Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory FunctionCompletedNCT00444106Phase 4Results posted
- Drug-drug Interaction Study of Ganaplacide and Lumefantrine With EfavirenzCompletedNCT05330273Phase 1
- Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and DolutegravirCompletedNCT05236530Phase 1
- Drug-drug Interaction Study of Ganaplacide and Lumefantrine With ItraconazoleCompletedNCT05084651Phase 1
- Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge ModelCompletedNCT04072302Phase 1
- Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to MosquitosTerminatedNCT02543086Phase 1
- Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infectionCompletedNCT01524341Phase 2
- Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With MalariaCompletedNCT01228344
- Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Uncomplicated P. Falciparum MalariaCompletedNCT00709969Phase 3
- Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.CompletedNCT00386763Phase 3
- Safety of Artemether - Lumefantrine, and Other Malaria Drugs and Their Effect on the Auditory FunctionTerminatedNCT00386750Phase 4
- Efficacy, Safety and Tolerability of Co-artemether in Non-immune TravelersCompletedNCT00233337Phase 4